Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Cholestasis: drug therapy]

U Leuschner1

  • 1Medizinische Klinik II, Johann-Wolfgang-Goethe-Universität, Frankfurt am Main.

Praxis
|December 19, 1998
PubMed
Summary
This summary is machine-generated.

Ursodeoxycholic acid is a successful treatment for cholestasis, unlike other therapies. Lifelong administration is necessary to prevent rebound cholestasis, with no reported side effects.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Direct dissolution of gallbladder stones with methyl tert-butyl ether (MTBE).

Revista de investigacion clinica; organo del Hospital de Enfermedades de la Nutricion·2009
Same author

Dissolution of cholesterol gallbladder stones with bile salts.

Revista de investigacion clinica; organo del Hospital de Enfermedades de la Nutricion·2009
Same author

[Extrahepatic manifestations of liver diseases: skeleton].

Praxis·2006
Same author

Ursodeoxycholic acid in the therapy for primary biliary cirrhosis: effects on progression and prognosis.

Zeitschrift fur Gastroenterologie·2005
Same author

Drug therapy of primary biliary diseases: classical and modern strategies.

Journal of cellular and molecular medicine·2002
Same author

Medical treatment of primary biliary cirrhosis and primary sclerosing cholangitis.

Digestion·2002
Same journal

Praxis·2026
Same journal

[What do Swiss doctors think about cardiovascular risk factors and guidelines?]

Praxis·2026
Same journal

[Laser interstitial thermotherapy (LITT): a minimally invasive neurosurgical treatment option for brain tumours and radiation necrosis].

Praxis·2026
Same journal

[Persistent back pain after lifting trauma. From the trivial to the rare case].

Praxis·2026
Same journal

[A patient with dizziness and gait instability - a diagnostic challenge].

Praxis·2026
Same journal

[Meningoencephalitis caused by listeria monocytogenes].

Praxis·2026
See all related articles

Area of Science:

  • Hepatology
  • Gastroenterology
  • Pharmacology

Context:

  • Cholestasis treatment historically involved plant alkaloids, phenobarbital, and S-adenosyl-L-methionine (SAMe).
  • Previous treatments showed limited success in managing cholestasis.
  • Ursodeoxycholic acid (UDCA) emerged as a physiologically occurring bile acid with therapeutic potential.

Purpose:

  • To evaluate the efficacy of ursodeoxycholic acid in treating cholestasis.
  • To compare UDCA's effectiveness against existing cholestasis therapies.
  • To assess the long-term impact and safety of UDCA therapy.

Summary:

  • Ursodeoxycholic acid (UDCA) is a successful treatment for cholestasis, with a recommended dosage of 10-15 mg/kg/day.
  • UDCA significantly improved symptoms, reduced cholestasis enzymes and immunoglobulin M in primary biliary cirrhosis patients.

Related Experiment Videos

  • Long-term UDCA therapy led to improved liver histology and prolonged the time to liver transplantation.

    • Impact:

    • UDCA therapy requires lifelong adherence to prevent cholestasis rebound.
    • UDCA is associated with no side effects.
    • In primary sclerosing cholangitis, UDCA combined with endoscopic bile duct dilatation improves life expectancy.